Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention

Tamoxifen (TAM) is a selective estrogen receptor modulator that is widely used in the prevention and treatment of estrogen receptor‐positive (ER+) breast cancer. Its use has significantly contributed to a decline in breast cancer mortality, since breast cancer patients treated with TAM for 5 years exhibit a 30–50% reduction in both the rate of disease recurrence after 10 years of patient follow‐up and occurrence of contralateral breast cancer. However, in patients treated with TAM there is substantial interindividual variability in the development of resistance to TAM therapy, and in the incidence of TAM‐induced adverse events, including deep vein thrombosis, hot flashes, and the development of endometrial cancer. This article will focus on the UDP glucuronosyltransferases, a family of metabolizing enzymes that are responsible for the deactivation and clearance of TAM and TAM metabolites, and how interindividual differences in these enzymes may play a role in patient response to TAM.

[1]  Moshe Finel,et al.  The Configuration of the 17-Hydroxy Group Variably Influences the Glucuronidation of β-Estradiol and Epiestradiol by Human UDP-Glucuronosyltransferases , 2008, Drug Metabolism and Disposition.

[2]  R. Fujiwara,et al.  Expression of UGT1A and UGT2B mRNA in Human Normal Tissues and Various Cell Lines , 2008, Drug Metabolism and Disposition.

[3]  S. Amin,et al.  Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases , 2007, Drug Metabolism and Disposition.

[4]  S. Amin,et al.  Elimination of Antiestrogenic Effects of Active Tamoxifen Metabolites by Glucuronidation , 2007, Drug Metabolism and Disposition.

[5]  C. Guillemette,et al.  Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid , 2006, Drug Metabolism and Disposition.

[6]  R. Dellinger,et al.  Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants , 2006, Breast Cancer Research.

[7]  Zeruesenay Desta,et al.  Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment , 2006, Clinical pharmacology and therapeutics.

[8]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Skaar,et al.  Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen , 2005, Cancer Chemotherapy and Pharmacology.

[10]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[11]  T. I. Apak,et al.  INTERACTIONS OF THE STEREOISOMERS OF α-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA , 2004, Drug Metabolism and Disposition.

[12]  T. A. Bell,et al.  Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. , 2004, Genomics.

[13]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[14]  K. Muro,et al.  Quaternary ammonium-linked glucuronidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. , 2004, Biochemical pharmacology.

[15]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[16]  Masaki Ito,et al.  Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity , 2004, Journal of Human Genetics.

[17]  Jia-Long Fang,et al.  Correlation between UDP-Glucuronosyltransferase Genotypes and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone Glucuronidation Phenotype in Human Liver Microsomes , 2004, Cancer Research.

[18]  T. Skaar,et al.  Gene expression profiles of 4‐hydroxy‐N‐desmethyl‐tamoxifen (endoxifen)‐ and 4‐hydroxy‐tamoxifen (4OHTAM)‐treated human breast cancer cells determined by CDNA microarray analysis , 2004 .

[19]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[20]  JK Coller.  Oxidative metabolism of tamoxifen to Z‐4‐hydroxy‐tamoxifen by cytochrome P450 isoforms: An appraisal of in vitro studies , 2003, Clinical and experimental pharmacology & physiology.

[21]  S. Kim,et al.  Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. , 2003, Chemical research in toxicology.

[22]  J. Muscat,et al.  Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk , 2003, Cancer.

[23]  A. Howell,et al.  New approaches to the endocrine prevention and treatment of breast cancer , 2003, Cancer Chemotherapy and Pharmacology.

[24]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[25]  G. Hynd,et al.  CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat and human liver microsomes , 2003, Xenobiotica; the fate of foreign compounds in biological systems.

[26]  Guangping Chen,et al.  4‐Hydroxytamoxifen sulfation metabolism , 2002, Journal of biochemical and molecular toxicology.

[27]  K. Turteltaub,et al.  Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. , 2002, Carcinogenesis.

[28]  C. Falany,et al.  Effects of dexamethasone on aryl (SULT1A1)- and hydroxysteroid (SULT2A1)-sulfotransferase gene expression in primary cultured human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[29]  M. Eichelbaum,et al.  The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. , 2002, British journal of clinical pharmacology.

[30]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[31]  R. Tukey,et al.  Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. , 2002, Pharmacogenetics.

[32]  K. Muro,et al.  Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. , 2002, Biochemical pharmacology.

[33]  Philip Lazarus,et al.  Glucuronidation: an important mechanism for detoxification of benzo[a]pyrene metabolites in aerodigestive tract tissues. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[34]  D. Hum,et al.  Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. , 2001, Endocrinology.

[35]  S. Murphy,et al.  O-Glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[36]  H. Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[37]  M. Green,et al.  Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[38]  R. Millikan,et al.  Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. , 2000, Cancer research.

[39]  H. Gschaidmeier,et al.  Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. , 1999, Drug metabolism reviews.

[40]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[41]  J. Cerhan,et al.  Tamoxifen therapy for breast cancer and endometrial cancer risk. , 1999, Journal of the National Cancer Institute.

[42]  B. Burchell,et al.  Molecular genetic basis of Gilbert’s syndrome , 1999, Journal of gastroenterology and hepatology.

[43]  M. Sales,et al.  Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase. , 1999, The Biochemical journal.

[44]  D. Hum,et al.  Characterization and substrate specificity of UGT2B4 (E458): a UDP-glucuronosyltransferase encoded by a polymorphic gene. , 1999, Pharmacogenetics.

[45]  M. Manns,et al.  Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. , 1999, The Biochemical journal.

[46]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[47]  M. Green,et al.  Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[48]  H. Jick,et al.  Tamoxifen and risk of idiopathic venous thromboembolism. , 1998, British journal of clinical pharmacology.

[49]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[50]  M. Ciotti,et al.  Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. , 1997, Pharmacogenetics.

[51]  S. Dehal,et al.  CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. , 1997, Cancer research.

[52]  M. Manns,et al.  Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. , 1997, Molecular pharmacology.

[53]  M. Green,et al.  Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. , 1997, Pharmacogenetics.

[54]  C. Falany.  Enzymology of human cytosolic sulfotransferases , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  G. Tucker,et al.  Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. , 1997, Biochemical pharmacology.

[56]  M. Green,et al.  Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[57]  H. Johansson,et al.  Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.

[58]  T. Iyanagi,et al.  Drug-responsive and tissue-specific alternative expression of multiple first exons in rat UDP-glucuronosyltransferase family 1 (UGT1) gene complex. , 1995, Journal of biochemistry.

[59]  M. Carcangiu.  Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[60]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[61]  M. Rowlands,et al.  Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[62]  L. Rutqvist,et al.  Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[63]  S. Povey,et al.  Localization of a bile acid UDP-glucuronosyltransferase gene (UGT2B) to chromosome 4 using the polymerase chain reaction. , 1992, Genomics.

[64]  P. Lønning,et al.  Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer , 1992, Clinical pharmacokinetics.

[65]  C. McDonald,et al.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.

[66]  P. Beaune,et al.  Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. , 1991, Biochemical pharmacology.

[67]  S. Lundgren,et al.  Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. , 1989, Cancer research.

[68]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[69]  P. Ueland,et al.  Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. , 1988, Cancer research.

[70]  V. Jordan,et al.  A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. , 1977, The Journal of endocrinology.

[71]  L. Lehmann,et al.  Gene expression of 17beta-estradiol-metabolizing isozymes: comparison of normal human mammary gland to normal human liver and to cultured human breast adenocarcinoma cells. , 2008, Advances in experimental medicine and biology.

[72]  Yannick Duguay,et al.  Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. , 2006, Cancer research.

[73]  D. Doerge,et al.  Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[74]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[75]  T. Tephly,et al.  The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[76]  J. Ritter,et al.  Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. , 1995, Progress in nucleic acid research and molecular biology.

[77]  C. Redmond,et al.  Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.

[78]  K. Bock.  Roles of UDP-glucuronosyltransferases in chemical carcinogenesis. , 1991, Critical reviews in biochemistry and molecular biology.

[79]  B. Katzenellenbogen,et al.  Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.

[80]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.